Are the available low-molecular-weight heparin preparations the same?

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue SUPPL. 1, 1996, Pages 77-91

  Fareed, Jawed ^a   Jeske, Walter ^a   Hoppensteadt, Debra ^a   Clarizio, Rana ^a   Walenga, Jeanine M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antithrombin; Low molecular weight heparin; Prophylaxis; Thromboembolic diseases; Thrombosis; Tissue factor pathway inhibitor

Indexed keywords

ANTICOAGULANT AGENT; APROTININ; ARDEPARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BOXOL; CERTOPARIN; DALTEPARIN; ENOXAPARIN; GLYCOSAMINOGLYCAN; LOW MOLECULAR WEIGHT HEPARIN; MINIPARIN; NADROPARIN; PARNAPARIN; PROTAMINE; REVIPARIN; TINZAPARIN; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; DOSE TIME EFFECT RELATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS;

EID: 0029780448     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Fareed J, JM Walenga, A Kumar, A Rock: A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemostas 11:155, 1985.
2. Fareed J, D Hoppensteadt, X Huan, A Racanelli: Comparative study on the in vitro and in vivo activities of seven low molecular weight heparins. Haemostasis 18 (Suppl 3):3, 1989.
3. Abildgaard U, P Sandset, A Lindahl: Tissue factor pathway inhibitor. In: Poller L (Ed): Recent Advances in Blood Coagulation. Churchill Livingstone, Edinburgh, 1993, pp. 105-124.
4. Broze GJ: Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag Fibrinolysis 6:S7, 1995.
5. Van Dedem G, JI Nielsen: Determinations of the molecular mass of low molecular mass (LMM) heparin. Pharmeuropa 3:202, 1991.
6. Fareed J, JM Walenga, M Lassen, L Borris, DA Hoppensteadt: Pharmacologic profile of a low molecular weight heparin (Enoxaparin): Experimental and clinical validation of the prophylactic antithrombotic effects. Acta Chir Scand 156(Suppl 556):75, 1990.
7. Cade JF, MR Buchanan, B Boneu, P Oekelford: A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the preparation. Thromb Res 35:613, 1984.
8. Fareed J, A Kumar, A Rock, JM Walenga, P Davis: A primate model (macaca mulatta) to study the pharmacokinetics of heparin and its fractions. Semin Thromb Hemostas 11:138, 1985.
9. Raake W, H Elling: Rat jugular vein hemostasis - a new model for testing antithrombotic agents. Thromb Res 53:73, 1989.
10. Barrowcliffe TW: Annotation: Low molecular weight heparins. Br J Haematol 90:1, 1995.
11. Lindahl AK, U Abildgaard, ML Larsen, LM Aamodt, O Nordfang, TC Beck: Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin-induced coagulation. Thromb Res 64:155, 1991.
12. Abildgaard U: Relative role of tissue factor pathway inhibitor and antithrombin in the control of thrombogenesis. Blood Coag Fibrinolysis 6:545, 1995.
13. Broze GJ Jr: Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag Fibrinolysis 6:S7, 1995.
14. Hoppensteadt DA, W Jeske, J Fareed, EW Bermes Jr: The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low molecular weight heparin. Blood Coag Fibrinolysis 6:S57, 1995.
15. Bognacki J, J Hammelburger: Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coag Fibrinolysis 6:S65, 1995.
16. Lindahl AK, PM Sandset, U Abildgaard: The present status of tissue factor pathway inhibitor. Blood Coag Fibrinolysis 3:439, 1992.
17. Petersen CC, SE Bjorn, O Nordfang: Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemostas 67:537, 1992.
18. Jeske W, D Hoppensteadt, R Klauser, A Kammereit, P Eckenberger, S Haas, P Wyld, J Fareed: Effect of repeated aprosulate and enoxaparin administration on TFPI antigen levels. Blood Coag Fibrinolysis 6:119, 1995.
19. Hoppensteadt D, JM Walenga, A Fasanella, W Jeske, J Fareed: TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 77:175, 1995.
20. Fareed J: Basic and applied pharmacology of low molecular weight heparins. Pharmacy Therap 16s-24s, 1995.
21. Fareed J, JM Walenga, R Pifarre: Newer approaches to the pharmacologic management of acute myocardial infarction. Cardiac Surg 6:101, 1992.
22. Fareed J, D Callas, D Hoppensteadt, W Jeske, JM Walenga: Recent developments in antithrombotic agents. Exp Opin Invest Drugs 4:389, 1995.
23. Fareed J, JM Walenga, DA Hoppensteadt, A Racanelli, E Coyne: Chemical and biochemical heterogeneity in low molecular weight heparins: Implications for clinical use and standardization. Semin Thromb Hemostas 15:440, 1989.
24. Fareed J, JM Walenga, R Pifarre: Newer approaches to the pharmacologic management of acute myocardial infarction. Cardiac Surg State Art Rev 6:101, 1992.
25. Hirsh J, S Siragusa, B Cosmi, JS Ginsberg: Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemostas 74:360, 1995.
26. Hanke H, M Oberhoff, S Hanke, S Hassenstein, J Kamenz, KM Schmid, E Betz, KR Karsh: Inhibition of cellular proliferation after experimental balloon angioplasty by low molecular weight heparin. Circulation 85:1548, 1992.
27. Schmid KM, M Preisack, W Voelker, M Sujatta, KR Karsch: First clinical experience with low molecular weight heparin LU 47311 (Reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty. Semin Thromb Hemostas 19:155, 1993.
28. Kakkar VV: Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE). Thromb Haemostas 74:368, 1995.
29. Fareed J, D Hoppensteadt, JM Walenga: A perspective on low molecular weight heparins in the management of thrombosis. Haemostaseologie 13:S5, 1993.
30. Letter to the Editor: Differentiation of beef and pig mucosal heparins by NMR spectroscopy. Thromb Haemostas 74:1197, 1995.
31. Fareed J, D Hoppensteadt, L Iyer: Impact of biotechnology in the diagnostic and therapeutic management of cardiovascular disorders. In: Longnecker JB (Ed): Nutrition and Biotechnology in Heart Disease and Cancer. Plenum Press, New York, 1995, pp 213-223.
32. Fareed J, D Callas, D Hoppensteadt, W Jeske, JM Walenga: Recent developments in antithrombotic agents. Exp Opin Invest Drugs 4:389, 1995.
33. Agnelli G, A Iorlo, C Renga, E Boschetti, GG Nenci, FA Ofosu: Prolonged antithrombin activity of low molecular weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation 92:2819, 1995.
34. Hirsh J, R Raschke R, TE Warkentin, JE Dalen, D Deykin, L Poller: Heparin: Mechanism of action, pharmacokinetics, dosing, considerations, monitoring, efficacy, and safety. Chest 108(Suppl): 258S, 1995.